secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001213900-23-087921
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix announces FDA approval of DefenCath to reduce catheter-related bloodstream infections in hemodialysis patients
--------------------------------------------------------------------------------

- DefenCath (taurolidine and heparin) is the first FDA-approved antimicrobial catheter lock solution for adult hemodialysis patients.
- Phase 3 LOCK-IT-100 trial showed a statistically significant 71% reduction in risk of CRBSIs (Hazard Ratio 0.29).
- DefenCath is expected to be available in Q1 2024 in the inpatient setting.
- The study enrolled 806 patients and early termination was recommended due to demonstrated efficacy.
- CorMedix (CRMD) prepares for commercial launch with healthcare providers and facilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023087921/0001213900-23-087921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023087921/ea188579-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-087921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer